Rationale: Apoptotic cell phagocytosis (efferocytosis) is mediated by specific receptors and is essential for resolution of inflammation. In chronic inflammation, apoptotic cell clearance is dysfunctional and soluble levels of several apoptotic cell receptors are elevated. Reports have identified proteolytic cleavage as a mechanism capable of releasing soluble apoptotic cell receptors, but the functional implications of their proteolysis are unclear.
E fficient phagocytosis of apoptotic cells (efferocytosis)
is an essential component of tissue homeostasis, wound healing, and the resolution of inflammation. Professional phagocytes, such as macrophages, use a variety of transmembrane receptors to rapidly recognize and ingest apoptotic cells. 1 After engulfing an apoptotic cell, macrophages actively dampen inflammation by releasing anti-inflammatory cytokines, such as transforming growth factor-β and interleukin-10, as well as proresolving lipid mediators and eicosanoids that promote macrophage efflux and the resolution of inflammation. 2, 3 However, if apoptotic cells are not rapidly cleared, secondary necrosis ensues, resulting in leakage of toxic intracellular antigens, tissue damage, and amplified inflammation.
Defective efferocytosis is frequently observed in the context of chronic inflammation, with pathological sequelae ranging from nonresolving foot ulcers in diabetes mellitus to necrotic core expansion in atherosclerosis. 4, 5 However, the underlying mechanisms responsible for deficient apoptotic cell uptake are poorly understood. receptor (LOX)-1. [6] [7] [8] CD36 is a dual-pass transmembrane receptor, 9 whereas MerTK 10 and LOX-1 11 are type I and type II transmembrane proteins, respectively. MerTK and LOX-1 can be proteolytically cleaved by the transmembrane protease ADAM17. 12, 13 Although the ubiquitously expressed ADAM17 was first described for its role in the shedding of cell-associated tumor necrosis factor-α, 14, 15 it has since been shown to cleave a variety of cell surface proteins involved in inflammation. 16, 17 Regulation of ADAM17 is poorly understood, and lack of reagents to monitor its levels and activity have hampered progress. Unlike soluble enzymes that cleave substrates at specific consensus sequences, ADAM17 cleaves its substrates at a membrane-proximal site in which stalk length and distance from the membrane seem to be important. 18 ADAM17 membrane proximal cleavage of its substrates releases almost the entire extracellular domain, and the soluble ectodomain can often act as an antagonist, which has been shown for LOX-1 and MerTK. 19, 20 Thus, proteolysis of apoptotic cell receptors has the potential to rapidly decrease receptor surface levels and release a soluble antagonist, both of which could exacerbate deficient efferocytosis. However, the functional contribution of proteolysis to the regulation of apoptotic cell uptake in vivo has not been tested.
The current investigation tests the hypothesis that efferocytosis and its concomitant anti-inflammatory consequences are limited by proteolytic cleavage of apoptotic cell receptors from the macrophage surface. We show that ADAM17 deletion enhances macrophage-mediated efferocytosis in vivo, resulting in an augmented anti-inflammatory response. In addition, we report that macrophage CD36 surface levels are elevated in the absence of ADAM17, and that there are 3 probable N-terminal cleavage sites in CD36. The absence of ADAM17 leads to a decrease in soluble CD36 levels. Blockade of CD36 in vivo is sufficient to abolish enhanced efferocytosis by Adam17-null macrophages, a process which also accelerates resolution of inflammation. Together these studies establish that ADAM17-mediated proteolysis of CD36 is an important post-translational mechanism controlling apoptotic cell phagocytosis, inflammation, and its resolution.
Methods
An expanded Methods section describing all procedures is available in the Online Data Supplement.
Hematopoietic Chimeric Mice
Adam17 ΔEx5/ΔEx5 (Adam17 -/-) or wild-type (WT) hematopoietic chimeras were generated as previously described using C57BL/6 embryonic stem cells. 21, 22 All mouse experiments were approved by the University of Washington Institutional Animal Care and Use Committee.
Sterile Peritonitis Model
Thioglycollate peritonitis was induced by injection of 1 mL of 4% sterile thioglycollate (BD Diagnostic, 2321398). Peritoneal cells (thioglycollate-elicited cells) were collected after 4 days by injection and removal of 5 mL phosphate buffered saline (PBS) containing 5 mmol/L EDTA.
Flow Cytometry
Staining of freshly isolated cells for flow cytometric analyses (FACScan, BD Pharmingen; 10-50 000 events) used antibodies listed in the Online Data Supplement. Flow data were analyzed using FlowJo 7.5 software (TreeStar).
Fab Preparation
Protein-L purified IgAs from hybridoma media (anti-CD36, Clone CRF-D 2717, Roy Silverstein), or nonimmune IgA (Sigma Aldrich, M-1421), were partially reduced to facilitate papain cleavage 23 and incubated with immobilized papain (Pierce, 20341) to generate Fab fragments.
In Vivo Efferocytosis
Thymuses (4-to 6-week C57BL/6 mice) were harvested, mechanically dissociated and filtered to yield a single-cell suspension. Thymocytes were labeled with mixed isomers of 5-(and-6)-carboxytetrametylrhodamine, succinimidyl ester (TAMRA-SE) (Molecular Probes, C-1171), and in vivo analysis of apoptotic cell uptake was performed. 24
Liposome Binding and Uptake
Phosphatidylserine (PS)-rich liposomes (equal parts PS to phosphatidylcholine) were prepared with a 1% mole fraction of the fluorescent dye, 1-dioctadecyl-3,3-tetramethylindocarbocyanin perchlorate (DiI, Sigma, 42364), by extrusion through a 0.1-μm polycarbonate membrane. 25 Thioglycollate-elicited cells from WT or ADAM17-null hematopoietic chimeras were plated, and macrophages (>95%) adherent after 2 hours were used for binding and uptake studies.
Soluble CD36 Characterization
Thioglycollate-elicited macrophages were plated 2 hours and adherent cells were cultured with 1 000 000 U/L human macrophage colony-stimulating factor (gift from Chiron), or other stimulants, in Opti-MEM (Invitrogen) for 4, 6, or 24 hours at 37°C. Conditioned media was centrifuged at 300g for 10 minutes to remove cell debris, followed by 28 300g for 140 minutes at 4°C to minimize microparticle content, 26 and levels of CD36 were determined by ELISA using antibodies recognizing the extracellular domain of CD36. The resulting media were directly run on SDS-PAGE for Western analysis, or immunoprecipitated and run on SDS-PAGE for mass spectrometry (MS).
Identification of Potential Cleavage Sites in Soluble CD36
Gel bands corresponding to CD36 were detected by Coomassie staining and were verified by CD36 immunoblot analysis of adjacent lanes. CD36 fractions were excised, subjected to standard in-gel digestion with trypsin, and digested peptides were analyzed by liquid chromatography-MS analysis.
Statistical Analysis
For statistical analysis, the Student t test was performed using the InStat software, version 3.0b. All error bars represent SE of the mean.
Results

In Vivo Efferocytosis Is Enhanced in Macrophages Lacking ADAM17
To test the hypothesis that efferocytosis and its downstream anti-inflammatory response are limited by proteolytic cleavage of macrophage apoptotic cell receptors, we evaluated the effect of leukocyte-specific deletion of the transmembrane protease ADAM17 on apoptotic cell phagocytosis in vivo. Adam17-null and WT hematopoietic chimeras were injected intraperitoneally with the sterile irritant thioglycollate to promote inflammatory monocyte influx. At 96 hours after thioglycollate, levels of cytokines released early in the response (2-4 hours) have abated and the influx of neutrophils has cleared (48 hours), leaving F4/80+ macrophages as the major leukocyte (>85%) in the peritoneal cavity. 21 Fluorescently labeled control or apoptotic thymocytes were injected into the peritoneum to evaluate efferocytosis ( Figure 1A) . No difference in thymocyte uptake between Adam17-null and WT macrophages is observed after injection of either healthy control or opsonized thymocytes ( Figure 1B ). In contrast, administration of apoptotic thymocytes demonstrates a 1.6fold increase in Adam17-null macrophage binding and uptake of apoptotic cells relative to WT ( Figure 1B ). Uptake of fluorescently labeled apoptotic thymocytes was confirmed by fluorescent microscopy (Online Figure 1 ). This significant increase in macrophage-mediated efferocytosis suggests that ADAM17 may directly or indirectly change levels of one or more apoptotic cell receptors. Mixed hematopoietic chimeras containing a 50% mixture of Adam17-null and WT bone marrow were evaluated to determine whether efferocytosis in the absence of ADAM17 is indirectly increased as a result of alteration of the extracellular inflammatory environment (eg, by soluble mediators). Although both Adam17-null and WT cells in the mixed chimeras are exposed to an identical extracellular milieu, Adam17-null macrophages still display enhanced efferocytosis ( Figure 1B) . These results indicate that the increase in apoptotic cell phagocytosis by Adam17-null macrophages is cell intrinsic and directly impacts apoptotic cell receptor function.
Nonstandard Abbreviations and Acronyms
Efferocytosis has been shown to actively inhibit the macrophage inflammatory response. 2 To evaluate whether elevated apoptotic cell uptake alters the inflammatory phenotype of Adam17-null macrophages, intracellular protein levels of arginase I and inducible nitric oxide synthase were compared by flow cytometry after injection of apoptotic thymocytes (representative histograms in Online Figure 2 ), healthy thymocytes, or PBS. After in vivo uptake of apoptotic cells, Adam17null macrophages show a 34% elevation in arginase I levels relative to WT ( Figure 1C ). In addition, subsequent inflammatory stimulation ex vivo leads to a 45% reduction in inducible nitric oxide synthase induction in the null macrophages ( Figure 1D ). No differences in arginase I or inducible nitric oxide synthase levels were observed in Adam17-null or WT macrophages injected with control thymocytes ( Figure 1C and 1D). Although we cannot eliminate the possibility that prior uptake of apoptotic neutrophils during the thioglycollate response may alter macrophage phenotype and efferocytosis, Adam17-null macrophages did not demonstrate altered arginase signaling detectable at 96 hours. Overall, ADAM17 deletion significantly augments the macrophage efferocytosisinduced anti-inflammatory phenotype.
Increased Phosphatidylserine Liposome Binding/ Uptake by Adam17-Null Macrophages Is CD36 Dependent and Is Associated With Elevated CD36 Surface Levels
Macrophages express a variety of apoptotic cell receptors that may be modulated by ADAM17. Because macrophage efferocytosis is dependent on apoptotic cell receptor recognition of PS exposed by cells undergoing apoptosis, 2 PS liposomes were used as a surrogate for apoptotic cells for an in vitro screen of potential receptors responsible for the enhanced efferocytosis by Adam17-null macrophages. Adam17-null peritoneal macrophages bind more PS liposomes in vitro ( Figure 2A and 2C), but not phosphatidylcholine liposomes (data not shown), suggesting that ADAM17 deletion results in elevated levels of receptors that recognize PS exposed Figure 1 . Increased in vivo efferocytosis of apoptotic thymocytes by Adam17-null macrophages is cell autonomous and shifts them to a less inflammatory phenotype. A, The scheme for in vivo peritoneal macrophage uptake of TAMRAlabeled apoptotic thymocytes is shown (intraperitoneal [IP]). Healthy thymocytes and opsonized thymocytes were evaluated as controls. B, Wild-type (WT), Adam17-null, or mixed hematopoietic chimera mice that have ≈50% WT and ≈50% Adam17-null leukocytes were injected with the indicated thymocytes. The percentage of TAMRA-positive macrophages was assessed by flow cytometry. C, After in vivo exposure to phosphate buffered saline (PBS), healthy or apoptotic thymocytes, Adam17-null, or WT macrophages were analyzed immediately after harvest for intracellular levels of arginase I, or D, Cultured ex vivo for 20 hours with lipopolysaccharide and interferon γ and analyzed for intracellular inducible nitric oxide synthase (iNOS) by flow cytometry. Numbers in the bars indicate the number of mice evaluated, and P values for significant differences are shown. on apoptotic cells. Similar results were obtained with Adam17-null versus WT bone-marrow-derived macrophages ( Figure 2B ). Although many apoptotic cell receptors can bind PS, a unique subset of receptors shares an affinity for acetylated LDL as a ligand. When acetylated LDL is added with PS liposomes, the ADAM17-dependent difference in PS liposome binding is abolished (Figure 2A ). This finding suggests that the receptors responsible for elevated liposome binding by Adam17-null macrophages have the ability to directly bind both acetylated LDL and PS liposomes-a trait shared by CD36 and scavenger receptor (SR)-B1. 27 However, SR-B1 surface levels were not detectable above isotype control staining of WT or Adam17-null macrophages (data not shown), thus focusing our attention on CD36.
To first directly test the role of CD36 in the enhanced in vitro liposome binding and uptake by Adam17-null macrophages, the extent of inhibition by anti-CD36 or isotype control antibody was evaluated ( Figure 2C ). CD36 blockade abolishes the differential liposome uptake by Adam17-null peritoneal macrophages and significantly reduces uptake by both Adam17-null and WT macrophages. In contrast, blocking antibody to SR-A, a prominent scavenger receptor, has no significant effect. Together these data identify CD36 as the primary apoptotic cell receptor leading to enhanced PS liposome binding and uptake in vitro by Adam17-null macrophages.
To more broadly screen for possible changes in apoptotic cell receptor surface levels, freshly isolated thioglycollateelicited peritoneal macrophages from WT and Adam17-null chimeras were analyzed by flow cytometry. ADAM17 deletion results in a 30% increase in macrophage surface CD36 but no difference in other apoptotic cell receptors ( Figure 3A) , although MerTK, LOX-1, and SR-phosphatidylserine and oxidized LDL are reported substrates of ADAM17. 12, 13, 28 CD36 surface levels are elevated to a similar extent on Adam17-null macrophages from mixed hematopoietic chimeras (data not shown), indicating a cell autonomous trait. Interestingly, CD36 surface levels are low in resident peritoneal macrophages but increase after thioglycollate injection, reaching a maximum at 96 hours ( Figure 3B -3D). These results suggest that CD36 may be important during the resolution phase of inflammation. 2, 29 Also, no difference in CD36 mRNA levels is observed by quantitative polymerase chain reaction analysis of Adam17-null and WT macrophages (data not shown), suggesting that ADAM17-dependent mechanisms regulate CD36 surface levels post-translationally. The combined data showing an acetylated LDL-sensitive increase in PS liposome binding and uptake by Adam17-null macrophages, as well as elevated CD36 surface levels, implicate CD36 as a major target of ADAM17.
ADAM17 Deletion Reduces Levels of Soluble CD36
Elevated macrophage CD36 surface levels would be expected to coincide with decreased release of soluble CD36. To evaluate whether levels of soluble CD36 are altered by ADAM17 deficiency, 24-hour conditioned media were collected from adherent Adam17-null and WT peritoneal macrophages. To reduce potential microvesicle content, the media were centrifuged at high speed, which depletes microvesicles by ≈75%. 26 Quantification of media CD36 levels by ELISA using antibodies to the CD36 extracellular domain shows that ADAM17 deletion reduces the ratio of soluble/cellular CD36 by 25.8% ( Figure 4A ). Soluble forms of CD36 are not a result of alternative splicing because this has been shown to occur in the 5ʹ noncoding region in all identified variants. 30 Release of soluble CD36 from WT peritoneal macrophages was also investigated after 4-hour stimulation with PBS, lipopolysaccharide, and interleukin-4 ( Figure 4B ). Although shedding of tumor necrosis factor receptor II, another substrate of ADAM17, was increased >5-fold after lipopolysaccharide stimulation ( Figure 4B ), neither lipopolysaccharide nor interleukin-4 increased levels of soluble CD36 relative to PBS, suggesting its release is primarily constitutive.
Because CD36 is a highly glycosylated protein, Western analysis was performed after PNGase F treatment of media samples to assess molecular species (Figure 4C and 4D) . . Adam17-null peritoneal and bone marrow-derived macrophages show increased phosphatidylserine liposome binding/uptake, and peritoneal macrophage uptake is CD36 dependent. A, Peritoneal macrophages from wildtype (WT) or Adam17-null hematopoietic chimera mice were harvested 96 hours after thioglycollate injection, plated and treated either with or without acetylated low-density lipoprotein (acLDL) at 4°C for 15 minutes followed by incubation with 40 µmol/L fluorescently labeled phosphatidylserine (PS) liposomes for 4 hours at 4°C. B, Bone marrow-derived macrophages were isolated from whole bone marrow of WT or Adam17-null hematopoietic chimera mice and cultured for 7 days with macrophage colony-stimulating factor. Adherent cells were replated, and PS liposome binding was monitored as described in A. C, Peritoneal macrophages were plated and incubated with 160 µmol/L fluorescently labeled PS liposomes and 5 mg/L of either receptor-blocking or isotype control antibody for 1 hour at 37°C. Fluorescence was assessed by flow cytometry, numbers within the bars indicate the number of mice evaluated, and P values for significant differences are shown. June 21, 2013
Conditioned media (24 hours) from WT macrophages show primarily 2 regions of staining with apparent molecular weights of ≈52 and ≈47 kDa ( Figure 4C ). The ≈47-kDa region appears to be a doublet, although detection of 2 distinct species is variable. However, CD36 levels in both the ≈52and the ≈47-kDa regions are reduced in conditioned media from Adam17-null macrophages relative to WT. The ≈47-kDa region is also detected in 6-hour conditioned media ( Figure 4D ), consistent with it not being a degradation product of the longer 24-hour incubation. Together, these observations provide the first evidence for a role of ADAM17 in the proteolytic release of soluble CD36.
MS Identifies 3 Probable N-Terminal Cleavage Sites in Soluble CD36
CD36 is predicted to be a dual-pass transmembrane protein with considerable extracellular topology ( Figure 5A ). 9 To further characterize the species in soluble CD36 detected by Western analysis, conditioned media from WT macrophages were immunoprecipitated with anti-CD36 and 3 fractions were cut ( Figure 5B ) from the Coomassie-stained gel to include the ≈52-kDa region (fraction A), the zone between the 2 regions (fraction B), and the ≈47-kDa region (fraction C). In-gel tryptic digest followed by MS was performed on each of the excised gel fractions. MS unequivocally identified CD36 in all fractions with high sequence coverage (A, 31%; B, 34%; and C, 32%), and all peptides included segments of the extracellular domain ( Figure 5C ). The prediction would be that peptides from both the N-and C-terminal regions of the extracellular domain with nontryptic cleavage sites should be detected for soluble CD36.
Mass spectrometric analysis identified 3 N-terminal semitryptic peptides ( Figure 5A and 5C; Online Figure III ). Peptide N1 results from a nontryptic proteolytic cleavage between Gly23 and Gly24. This unique cleavage site is estimated to be 6 amino acids within the extracellular side of the putative N-terminal transmembrane domain (http://uniprot.org), which is not a typical cleavage site for ADAM17. 18 Cleavage 12 amino acids from the transmembrane domain between Glu41 and Val42, a more typical pattern for ADAM17, gives rise to peptide N2. Peptide N3 consists of amino acids 139 to 163 and contains the ADAM17 preferred amino acids alanine at the P1 position and valine at the P1ʹ position of the cleavage site as observed for several ADAM17 substrates, including tumor necrosis factor-α. 18 Although the N3 peptide is a greater distance from the transmembrane domain than other reported ADAM17 cleavage sites, it is adjacent to a hydrophobic region between amino acids 184 and 204 ( Figure 5A and 5C) that may interact with the plasma membrane. 9 Only 1 semitryptic peptide (C1) was identified in the C-terminal portion of CD36 ( Figure 5A and 5C; Online Figure IIID ). Because its cleavage site is 95 amino acids from the C-terminal transmembrane domain, ADAM17 cleavage at this site is unlikely. However, because ADAM17 may share cleavage sites with trypsin (http://merops.sanger.ac.uk), it is possible that some tryptic peptides actually result from ADAM17 cleavage, such as tryptic peptides with a C-terminal cleavage site at K426 and K430 ( Figure 4C ). The use of alternative enzymes for proteomics analysis would help address this issue. Nevertheless, our data provide strong evidence for proteolytic cleavage of CD36.
Increased In Vivo Apoptotic Cell Phagocytosis by Adam17-Null Macrophages Is CD36 Dependent and Promotes Accelerated Resolution of Inflammation
We next sought to directly test the contribution of CD36 to enhanced efferocytosis by Adam17-null macrophages in vivo. CD36-blocking or isotype control Fab was injected at the same time as the fluorescently labeled apoptotic thymocytes into the peritoneum of chimeras. Fab was used to avoid CD36 dimerization and activation that occurs with whole immunoglobulin A. 32 CD36 blockade significantly decreases efferocytosis by Adam17-null, but not WT, macrophages ( Figure 6A ). The absence of an effect on apoptotic cell uptake by WT macrophages in vivo as compared with in vitro liposome uptake ( Figure 2C ) may be because of a disparate response to whole immunoglobulin A used in the in vitro screen or differences in the effective dosage required in vivo. However, these in vivo data establish that CD36-mediated apoptotic cell phagocytosis is selectively enhanced in the absence of ADAM17.
To investigate in vivo relevance of enhanced efferocytosis by Adam17-null macrophages, we asked whether resolution of the inflammatory response was enhanced after injection of apoptotic thymocytes. Administration of apoptotic thymocytes led to a 33% reduction in the number of WT macrophages within 30 minutes ( Figure 6B) , indicating that apoptotic cell uptake enhances macrophage clearance and inflammation resolution. Injection of healthy thymocytes or PBS had no effect on macrophage numbers, suggesting no cell-intrinsic acceleration of macrophage exiting at 96 hours. In contrast to WT macrophages, Adam17-null macrophage numbers were reduced 56% in response to efferocytosis ( Figure 6B ), demonstrating accelerated exiting and highlighting the in vivo impact of increased apoptotic cell uptake in the absence of ADAM17.
Discussion
This study demonstrates for the first time that in vivo efferocytosis and its associated anti-inflammatory effects are enhanced by ADAM17 deletion, suggesting that ADAM17 normally functions to limit apoptotic cell phagocytosis. Unexpectedly, the major target of ADAM17 seems to be the dual-pass SR CD36; its surface levels are elevated in the absence of ADAM17 and the ratio of soluble to cell-associated CD36 is decreased by 25.8%. Further, in the sterile peritonitis model, we detect no Adam17-dependent alterations in surface levels of any other major apoptotic cell receptors, including LOX-1 and MerTK, which were previously implicated as substrates of ADAM17. 12, 13 Using MS, 3 novel N-terminal peptides and 1 C-terminal peptide were detected in soluble CD36 that represent probable cleavage sites. In addition, we establish that enhanced in vivo efferocytosis in the absence of ADAM17 is CD36 dependent and leads to accelerated clearance of macrophages. These data provide evidence for ADAM17 involvement in the shedding of a dual-pass transmembrane protein and demonstrate the importance of proteolysis in controlling apoptotic cell uptake and resolution of inflammation associated with apoptotic cell uptake.
Recent reports have shown that ADAM17 can cleave MerTK and LOX-1 in vitro, and thus they were particularly likely targets. 12, 13 However, we demonstrate no change in surface levels of either of these receptors in vivo, whereas CD36 levels are elevated in the absence of ADAM17. A likely explanation for the lack of effect on either MerTK or LOX-1 is that in vitro analyses have shown that their shedding requires stimulation with lipopolysaccharide or tumor necrosis factor-α, respectively. 12, 13 Thus, ADAM17 cleavage of MerTK and LOX-1 may play a more significant role in responses to pathogens and on classically activated macrophages.
The ADAM17-dependent correlation between macrophage CD36 surface levels and in vivo enhanced efferocytosis further highlights the importance of CD36 as an apoptotic cell receptor. Previous experiments in CD36-deficient mice established that apoptotic cell burden in wound tissue is 2to 3-fold greater than in WT mice, and in vitro efferocytosis was reduced by ≈40% in CD36-deficient macrophages. 33, 34 In our studies, elevated surface levels of CD36 in the absence Figure 4 . Adam17 deletion results in a 25% decrease in the ratio of soluble to cell-associated CD36. CD36 content and biochemical characteristics of microparticle-depleted conditioned medium and cell lysates from Adam17-null and wild-type (WT) peritoneal macrophages after the indicated incubation times were analyzed. A, CD36 levels in lysate and media were quantified by ELISA and expressed as the ratio of soluble to cellular CD36, and numbers within the bars indicate the number of mice of different genotypes whose macrophages were evaluated. These data are representative of 2 experiments. B, Soluble levels of CD36 and tumor necrosis factor (TNF) receptor II were evaluated by ELISA after stimulation of WT peritoneal macrophages for 4 hours. Data are expressed relative to levels in phosphate buffered saline (PBS). Values are from 2 different experiments using macrophages from different mice determined in duplicate. C and D, Western blot analysis of conditioned media from Adam17null or WT peritoneal macrophages after deglycosylation with peptide-N-glycosidase F. Each lane represents media collected from macrophages of different mice after the indicated time, and the collections for C are from a different experiment than shown in A. IL-4 indicates interleukin-4; and LPS, lipopolysaccharide. June 21, 2013 of ADAM17 led to increased apoptotic cell uptake by inflammatory macrophages in vivo, and we demonstrate that the majority of ADAM17-dependent enhanced efferocytosis is abolished by CD36 blockade. Low levels of expression of CD36 on resident tissue and peritoneal macrophages and highest CD36 expression on inflammatory macrophages during the resolution phase suggest that its role in efferocytosis may be more important for inflammatory responses than for normal homeostasis. Further, we show that acceleration of macrophage clearance from the peritoneum is dependent on apoptotic cell uptake. Together these data suggest a temporal and context-dependency for ADAM17 modulation of the resolution of inflammation.
To biochemically characterize soluble CD36, we analyzed media collected from cultured WT peritoneal macrophages, and our MS analysis uncovered 3 probable N-terminal cleavage sites. ADAM17 normally cleaves the extracellular stalk of its substrates proximal to the transmembrane domain (typically within 15 amino acids) with some preferences for particular residues flanking the cleavage site. 18 The nontryptic N terminus of peptide N1 is estimated to be 6 amino acids into the putative transmembrane domain, and, therefore, is less likely to be a direct target of ADAM17. Because we cannot distinguish between ADAM17 involvement in primary and secondary cleavage events, it is possible that initial ADAM17-dependent cleavage of CD36 at N2, N3, or another site leads to activation of regulated intramembrane proteolysis, such as that mediated by γ-secretases, 17 or that ADAM17 modulates cleavage by another protease and does not directly target CD36. With a cleavage site 12 amino acids from the transmembrane domain, peptide N2 is more typical of ADAM17 cleavage. In contrast, peptide N3 is 113 amino acids from the transmembrane domain, but 45 amino acids from a hydrophobic region of CD36 that may interact with the plasma membrane, 9 and thus may localize the N3 cleavage site in a juxtamembrane position that favors interaction with ADAM17 ( Figure 5A ). It also contains alanine and valine preferred by ADAM17 in the P1 and P1ʹ position, respectively. 18 Functionally, both N2 and N3 cleavage would likely disrupt the domain of CD36 (amino acids 155-183) implicated in macrophage phagocytosis of apoptotic cells. 35 We identified only 1 C-terminal nontryptic peptide (C1), and because it is 95 amino acids from the C-terminal transmembrane domain, it likely results from cleavage by an enzyme other than ADAM17. Because ADAM17 deletion only inhibits release of soluble CD36 by 25%, other proteases may Possible N-terminal ADAM17 cleavage sites are indicated with arrows. A, Hydrophobic region between amino acids 184 and 204 may interact with the plasma membrane, 9 creating additional regions adjacent to the plasma membrane. All of the cysteine residues in CD36 are shown as a solid circle, and dotted lines indicate disulfide bonds determined from mass spectrometry analysis. 31 CD36 domain data particularly implicate the C-terminal cytoplasmic domain in assembly of signaling complexes that mediate its multiple functions. 39, 40 This diagram was adapted from Silverstein and Febbraio. 9 B, Soluble CD36 immunoprecipitated from microparticle-depleted 24-hourconditioned media was separated on SDS-PAGE after peptide-Nglycosidase F treatment. Western analysis showing 3 gel fractions (A, B, and C) from the major regions of CD36 seen in Figure 4 and the area between were excised as indicated for mass spectrometric analysis. C, CD36 protein sequence is shown and peptides identified in the 3 gel slices are underlined, 2 putative transmembrane domains are in dark gray boxes, and a hydrophobic region that may interact with the plasma membrane is the gray box with dashed outline. The unique N-terminal peptides (N1, N2, and N3) and a C-terminal nontryptic peptide (C1) are indicated by open black boxes. All of the indicated peptides were identified in ≥2 of 3 separate samples.
be involved in liberation of soluble CD36, such as ADAM10 or multiple other ADAM proteases expressed by peritoneal and bone marrow-derived macrophages (Online Figure IV) . Detailed structural data for CD36 and a better understanding of its processing would facilitate interpretation of our data. Although we do not yet understand how soluble CD36 is released from the cell, our data collectively implicate ADAM17 in the shedding of CD36 and establish a role for ADAM17 in the regulation of surface levels of the ditopic transmembrane receptor CD36.
CD36 levels in serum are increased in several chronic inflammatory diseases and have been found to positively correlate with mortality, type 2 diabetes mellitus, and atherosclerotic disease severity. 8, 36, 37 However, the biochemical nature of soluble CD36 has not been evaluated in these contexts. A recent study suggested that the soluble CD36 found in the plasma of healthy donors is full-length CD36 and is a component of microparticles. 38 Although this study analyzed isolated fractions by Western blot analysis and failed to detect CD36 in the microparticle-depleted platelet-free plasma, 38 technical issues with the analysis of plasma may have limited the sensitivity of detection. Given the already robust correlations of soluble levels of CD36 with disease severity and early detection, 8, 36 we plan to investigate the relative distribution of soluble CD36 in microparticles and cleaved soluble forms in different disease states, which could significantly enhance their usefulness as biomarkers. Our analysis of WT macrophage conditioned media in vitro showed a relative distribution of 0.48±0.038% in media depleted of microparticles and 0.042±0.001% in the microparticle pellet after ultracentrifugation, both relative to cell lysate CD36 (n=3 per group). In the absence of ADAM17, CD36 in media was decreased 25.8% (P=0.011; n=3) and microparticle pellet content was increased by 14.3% (P=0.023; n=3). Our data suggest that under these in vitro conditions, shed CD36 in media is a more significant contributor than microparticle-derived CD36. More detailed biochemical analysis is needed to determine the extent to which soluble CD36 in chronic inflammatory diseases may result from ADAM17mediated shedding.
Our studies have focused on enhanced uptake of apoptotic cells in the absence of macrophage ADAM17 and identified CD36 as the primary apoptotic cell receptor targeted by ADAM17. The increased ADAM17-mediated CD36 shedding uncovered in our study may provide a mechanistic link between the nonresolving nature of certain diseases and defective apoptotic cell phagocytosis. However, in addition to apoptotic cell uptake, CD36 has several other functions, such as uptake of pathogens and modified LDLs important in inflammatory responses, including atherosclerosis, mediation of long-chain fatty acid uptake and transport into cells involved in metabolic disorders, and binding thrombospondin and related proteins to inhibit angiogenesis in wound healing and various pathologies. Essential to these 9 other functions is CD36 assembly of signaling complexes, most likely mediated by the C-terminal cytoplasmic domain. 39, 40 Proteolysis would disable this downstream pathway, and thus it is likely that this mechanism has even broader implications for inflammation and disease pathogenesis than has been uncovered in our investigations. Therefore, it will be important for future studies to define the role of proteolysis in the multiple additional functions of CD36 in normal homeostasis and pathology. Figure 6 . Enhanced efferocytosis by Adam17-null macrophages is abolished by CD36-blocking Fab and resolution of inflammation is accelerated in mice lacking leukocyte ADAM17. The in vivo apoptotic cell assay was performed as shown in Figure 1A . A, Fluorescently labeled apoptotic thymocytes, along with 80 µg of either isotype, or CD36-blocking Fab, were injected into the peritoneal cavity of Adam17-null and wild-type chimeric mice and TAMRA-positive macrophages assessed by flow cytometry. B, Total macrophage number in the peritoneal cavity was evaluated 30 minutes after injection of phosphate buffered saline (PBS), healthy thymocytes, or apoptotic thymocytes to monitor the resolution of inflammation. The number of mice analyzed (within bars) and P values of significant differences are shown.
